|
Market Closed -
Nasdaq
16:00:00 2026-11-13 EST
|
5-day change | 1st Jan Change | ||
| 0.9999 USD | -0.01% |
|
-2.92% | -57.09% |
| 11-12 | Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| 11-10 | Spero Therapeutics, Inc. Announces Board and Committee Changes | CI |
Company Valuation: Spero Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 517.5 | 89.57 | 77.91 | 56.15 | 131.3 | 58.23 | - | - |
| Change | - | -82.69% | -13.02% | -27.92% | 133.77% | -55.64% | - | - |
| Enterprise Value (EV) | 371.1 | 89.57 | 77.91 | 56.15 | 131.3 | 58.23 | 58.23 | 58.23 |
| Change | - | -75.86% | -13.02% | -27.92% | 133.77% | -55.64% | 0% | 0% |
| P/E | -5.5x | -1.41x | 3.42x | -0.81x | 15.5x | -1.72x | -9.52x | -0.97x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | -0x | 0x | -0x | 0x | 0.1x | -0x |
| Capitalization / Revenue | 28.3x | 1.67x | 0.75x | 1.17x | - | 194x | - | - |
| EV / Revenue | 0x | 0x | 0x | 0x | - | 194x | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | -0x | - | -0.86x | -1.15x | -0.95x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.91 | -1.23 | 0.43 | -1.27 | 0.15 | -0.58 | -0.105 | -1.03 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.26 | 53.51 | 103.8 | 47.98 | - | 0.3 | - | - |
| EBITDA | -87.32 | - | - | - | - | - | - | - |
| EBIT 1 | -87.97 | -42.2 | 21.48 | -73.36 | - | -67.8 | -50.75 | -61.2 |
| Net income 1 | -89.76 | -46.42 | 22.81 | -68.57 | - | -33.46 | -54.25 | -65.4 |
| Net Debt | -146.4 | - | - | - | - | - | - | - |
| Reference price 2 | 16.0100 | 1.7300 | 1.4700 | 1.0300 | 2.3300 | 0.9999 | 0.9999 | 0.9999 |
| Nbr of stocks (in thousands) | 32,324 | 51,776 | 52,999 | 54,518 | 56,339 | 58,235 | - | - |
| Announcement Date | 3/31/22 | 3/30/23 | 3/13/24 | 3/27/25 | 3/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.72x | - | - | - | 58.23M | |
| 17.35x | 6.64x | 12.72x | 1.72% | 66.33B | |
| 32.78x | 8.77x | 28.98x | 0.07% | 60.62B | |
| 38.6x | 6.87x | 20.53x | 0.84% | 55.5B | |
| 44.7x | 6.26x | 29.77x | -.--% | 47.58B | |
| 34.6x | 3.29x | 14.2x | -.--% | 43.69B | |
| -20.57x | 54.42x | -22.49x | -.--% | 37.27B | |
| 36.15x | 8.94x | 23.31x | 0.36% | 36.57B | |
| 40.59x | 7.89x | 26.33x | -.--% | 32.22B | |
| -73.93x | 14x | -75.29x | -.--% | 26.58B | |
| Average | 14.85x | 13.01x | 6.45x | 0.33% | 41B | |
| Weighted average by Cap. | 21.69x | 11.75x | 11.42x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRO Stock
- Valuation Spero Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
